CD274 and neoplasm: Although various clinical factors related to immunotherapy benefits and risk have been identified, such as PD‐L1 expression, tumor mutational burden (TMB), microsatellite instability‐high (MSI‐H), and neutrophil‐to‐lymphocyte ratio, none of these factors can alone accurately identify individuals who are most likely to have adverse outcomes and clinical benefit from immunotherapy.7, 8, 9, 10, 11